- Home
- ZVSA
as 03-28-2025 4:00pm EST
ZyVersa Therapeutics Inc is a clinical-stage biopharmaceutical company leveraging proprietary technologies to develop drugs for patients with chronic renal or inflammatory diseases with high unmet medical needs. The company has two proprietary globally licensed drug development platforms which are Cholesterol Efflux MediatorTM, VAR 200 (2-hydroxypropyl-beta-cyclodextrin) is an injectable drug in clinical development for the treatment of renal diseases. and IC 100 is a monoclonal antibody inflammasome ASC inhibitor in preclinical development for the treatment of inflammatory conditions.
| Founded: | 2014 | Country: | United States |
| Employees: | N/A | City: | SOMERVILLE |
| Market Cap: | 3.5M | IPO Year: | N/A |
| Target Price: | $240.00 | AVG Volume (30 days): | 426.1K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -8.48 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.60 - $8.05 | Next Earning Date: | 05-14-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest ZyVersa Therapeutics Inc. News
ZVSA Breaking Stock News: Dive into ZVSA Ticker-Specific Updates for Smart Investing
GlobeNewswire
4 days ago
ZyVersa Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update
GlobeNewswire
13 days ago
ZyVersa Therapeutics Highlights Data Published in the Journal of the American Heart Association Demonstrating Inflammasome Inhibition Attenuates Obesity-Associated Cardiomyopathy in Animal Model Study
GlobeNewswire
19 days ago
ZyVersa Therapeutics Highlights Data Demonstrating Inflammasome Inhibition Reduces Neuroinflammation and Pathological Brain Deposition of Amyloid Beta in Alzheimer’s Disease Mouse Model
GlobeNewswire
25 days ago
ZyVersa Therapeutics, Inc. Announces Pricing of $2.0 Million Private Placement Priced At The Market
GlobeNewswire
a month ago
ZyVersa Therapeutics Highlights Data Demonstrating NLRP3 Inflammasome Inhibition Reduces Inflammation, Improves Heart Function, and Restores Glucose Homeostasis and Insulin Sensitivity in Obese Animal Model of Heart Failure (HFpEF) and Type 2 Diabetes
GlobeNewswire
3 months ago
ZyVersa Therapeutics’ CEO, Stephen C. Glover, to Attend JPM’s Healthcare Conference 2025 in San Francisco
Zacks Small Cap Research
4 months ago
OTC Markets Hosts Virtual Investor Presentation with Stephen Glover, CEO of ZyVersa Therapeutics, Inc., with Brad Sorensen, Senior Analyst at Zacks SCR
GlobeNewswire
4 months ago
ZyVersa Therapeutics Announces Peer-Reviewed Publication Demonstrating That Inflammasome ASC Inhibitor IC 100 Protects Against Stroke-Related Cardiovascular Injury and Dysfunction in Preclinical Trial
Compare ZVSA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ZVSA ZyVersa Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.